Anti-angiogenic effect of bortezomib in patients with multiple myeloma.
Politou
Marianna
M
Department of Haematology, Faculty of Medicine Imperial College London, Hammersmith Hospital, London, UK.
Naresh
Kikkeri
K
Terpos
Evangelos
E
Crawley
Danielle
D
Lampert
Irvin
I
Apperley
Jane F
JF
Rahemtulla
Amin
A
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D006801:Humans; D008297:Male; D008833:Microcirculation / Q000187:drug effects / Q000473:pathology; D008875:Middle Aged; D009101:Multiple Myeloma / Q000098:blood supply* / Q000188:drug therapy* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011480:Protease Inhibitors / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use*; D012259:Ribonuclease, Pancreatic / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D042461:Vascular Endothelial Growth Factor A; D000069286:Bortezomib; C046366:angiogenin; D012259:Ribonuclease, Pancreatic